Skip to Main Content

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA)

Conditions

COVID-19 Inpatient | COVID-19 Outpatient

Phase COVID-III

What is the purpose of this trial?

This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.

  • Trial with
    Genentech, Inc.
  • Start Date
    09/23/2020
  • End Date
    07/30/2020
Trial Image

For more information about this study, contact:

Laurie Andrews

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/01/2020
  • Study HIC
    #2000028556